Regional differences in NET: Epidemiology, diagnosis, and referral strategies: Part 1
Вставка
- Опубліковано 10 вер 2024
- In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, and patient pathways, as well as look to future developments.
NETs are complex, rare diseases. Their optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. The best possible patient journey is impacted by regional differences in management strategies, referral pathways, and availability of diagnostic modalities and treatments.. Are you aware of the epidemiology of NETs and current best practices for diagnosis, referral strategies, and treatment for NETs? Or how regional differences can impact these?
Prof. Martyn Caplin is a Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center.
Catch the second episode, which explores different treatment options and modalities, as well as best practices on identifying which patients may benefit most from particular treatments using available biomarkers • Regional differences i...
Prefer to listen on the go?
Get the podcast audio of the experts in conversation and download the full transcript on the COR2ED website cor2ed.com/net... or listen on your favourite podcast platform:
Spotify: open.spotify.c...
Apple: podcasts.apple...
We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at nanets.net/
May 2024.
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen.
This podcast is developed by cor2ed.com